13 results on '"Andrew Bollen"'
Search Results
2. Systemic and Craniospinal Rosai Dorfman Disease with Intraparenchymal, Intramedullary and Leptomeningeal Disease
- Author
-
Yi Li, Emily Sloan, Andrew Bollen, David Solomon, Philip Theodosopoulos, and Soonmee Cha
- Subjects
Rosai Dorfman Disease ,Histiocytosis ,BRAF ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Rosai Dorfman disease is a rare histiocytic disorder of over-production of non-Langerhans histiocytes, which typically manifests with massive lymphadenopathy and sinonasal involvement. We report a rare case of systemic and disseminated craniospinal Rosai-Dorfman disease with intraparenchymal and leptomeningeal involvement, but no sinus or dural-based disease. The diagnosis was established by biopsy of a hypothalamic mass. Additionally, UCSF500 Next Generation Sequencing demonstrated a solitary pathogenic alteration affecting the BRAF oncogene, which supports the morphologic and immunohistochemical diagnosis of Rosai-Dorfman disease.
- Published
- 2021
- Full Text
- View/download PDF
3. Successful treatment of Balamuthia mandrillaris granulomatous amoebic encephalitis with the novel agent nitroxoline
- Author
-
Natasha Spottiswoode, Douglas Pet, Annie Kim, Katherine Gruenberg, Maulik Shah, Amrutha Ramachandran, Matthew Laurie, Maham Zia, Camille Fouassier, Christine Boutros, Rufei Lu, Yueyang Zhang, Venice Servellita, Andrew Bollen, Charles Chiu, Michael Wilson, Liza Valdivia, and Joseph DeRisi
- Abstract
This case report describes a survivor of Balamuthia mandrillaris granulomatous amoebic encephalitis (GAE) after treatment with the novel agent nitroxoline, a drug typically used to treat urinary tract infections. Nitroxoline was previously identified in a screen of US and European approved drugs for amoebicidal activity against this pathogen. We describe its successful first use in treating this rare and deadly disease.
- Published
- 2022
- Full Text
- View/download PDF
4. A genetically distinct pediatric subtype of primary CNS large B-cell lymphoma is associated with favorable clinical outcome
- Author
-
Ekin Güney, Calixto-Hope G. Lucas, Zhongxia Qi, Jingwei Yu, Ruth Zhang, Robert S. Ohgami, James L. Rubenstein, Daniel R. Boué, Kristian Schafernak, Gerald B. Wertheim, Sonika Dahiya, Lisa Giulino-Roth, Andishe Attarbaschi, Matthew J. Barth, Shalin Kothari, Oussama Abla, Adam L. Cohen, Joe S. Mendez, Andrew Bollen, Arie Perry, Tarik Tihan, Melike Pekmezci, David A. Solomon, and Kwun Wah Wen
- Subjects
Lymphoma, Non-Hodgkin ,Humans ,Hematology ,Lymphoma, Large B-Cell, Diffuse ,Child - Published
- 2021
5. Thiamine Deficiency-Mediated Brain Mitochondrial Pathology in Alaskan Huskies with Mutation in SLC19A3.1
- Author
-
Karen, Vernau, Eleonora, Napoli, Sarah, Wong, Catherine, Ross-Inta, Jessie, Cameron, Danika, Bannasch, Andrew, Bollen, Peter, Dickinson, and Cecilia, Giulivi
- Subjects
Models, Molecular ,Dogs ,Mutation ,food and beverages ,Animals ,Brain ,Membrane Transport Proteins ,Thiamine Deficiency ,Thiamine ,Nervous System Diseases ,DNA, Mitochondrial ,Article ,Mitochondria - Abstract
Alaskan Husky encephalopathy (AHE(1) ) is a fatal brain disease associated with a mutation in SLC19A3.1 (c.624insTTGC, c.625CA). This gene encodes for a thiamine transporter 2 with a predominately (CNS) central nervous system distribution. Considering that brain is particularly vulnerable to thiamine deficiency because of its reliance on thiamine pyrophosphate (TPP)-dependent metabolic pathways involved in energy metabolism and neurotransmitter synthesis, we characterized the impact of this mutation on thiamine status, brain bioenergetics and the contribution of oxidative stress to this phenotype. In silico modeling of the mutated transporter indicated a significant loss of alpha-helices resulting in a more open protein structure suggesting an impaired thiamine transport ability. The cerebral cortex and thalamus of affected dogs were severely deficient in TPP-dependent enzymes accompanied by decreases in mitochondrial mass and oxidative phosphorylation (OXPHOS) capacity, and increases in oxidative stress. These results along with the behavioral and pathological findings indicate that the phenotype associated with AHE is consistent with a brain-specific thiamine deficiency, leading to brain mitochondrial dysfunction and increased oxidative stress. While some of the biochemical deficits, neurobehavior and affected brain areas in AHE were shared by Wernicke's and Korsakoff's syndromes, several differences were noted likely arising from a tissue-specific vs. that from a whole-body thiamine deficiency.
- Published
- 2014
6. Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma
- Author
-
Jason M, Davies, Aaron E, Robinson, Cynthia, Cowdrey, Praveen V, Mummaneni, Gregory S, Ducker, Kevan M, Shokat, Andrew, Bollen, Byron, Hann, and Joanna J, Phillips
- Subjects
Male ,Proteome ,TOR Serine-Threonine Kinases ,Antineoplastic Agents ,Phosphorus ,Middle Aged ,Immunohistochemistry ,Article ,Oncogene Protein v-akt ,Disease Models, Animal ,Epitopes ,Mice ,Phosphatidylinositol 3-Kinases ,Mice, Inbred NOD ,Chordoma ,Animals ,Heterografts ,Humans ,Neoplasm Recurrence, Local ,Signal Transduction - Abstract
The management of patients with locally recurrent or metastatic chordoma is a challenge. Preclinical disease models would greatly accelerate the development of novel therapeutic options for chordoma. The authors sought to establish and characterize a primary xenograft model for chordoma that faithfully recapitulates the molecular features of human chordoma.Chordoma tissue from a recurrent clival tumor was obtained at the time of surgery and implanted subcutaneously into NOD-SCID interleukin-2 receptor gamma (IL-2Rγ) null (NSG) mouse hosts. Successful xenografts were established and passaged in the NSG mice. The recurrent chordoma and the derived human chordoma xenograft were compared by histology, immunohistochemistry, and phospho-specific immunohistochemistry. Based on these results, mice harboring subcutaneous chordoma xenografts were treated with the mTOR inhibitor MLN0128, and tumors were subjected to phosphoproteome profiling using Luminex technology and immunohistochemistry.SF8894 is a novel chordoma xenograft established from a recurrent clival chordoma that faithfully recapitulates the histopathological, immunohistological, and phosphoproteomic features of the human tumor. The PI3K/Akt/mTOR pathway was activated, as evidenced by diffuse immunopositivity for phospho-epitopes, in the recurrent chordoma and in the established xenograft. Treatment of mice harboring chordoma xenografts with MLN0128 resulted in decreased activity of the PI3K/Akt/mTOR signaling pathway as indicated by decreased phospho-mTOR levels (p = 0.019, n = 3 tumors per group).The authors report the establishment of SF8894, a recurrent clival chordoma xenograft that mimics many of the features of the original tumor and that should be a useful preclinical model for recurrent chordoma.
- Published
- 2013
7. Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging
- Author
-
Soonmee, Cha, Tarik, Tihan, Forrest, Crawford, Nancy J, Fischbein, Susan, Chang, Andrew, Bollen, Sarah J, Nelson, Michael, Prados, Mitchel S, Berger, and William P, Dillon
- Subjects
Adult ,Male ,Blood Volume ,Oligodendroglioma ,Contrast Media ,Brain ,Middle Aged ,Magnetic Resonance Imaging ,nervous system diseases ,Diagnosis, Differential ,Humans ,Female ,neoplasms ,Aged - Abstract
BACKGROUND AND PURPOSE: Histopathologic evaluation remains the reference standard for diagnosis of glioma and classification of histologic subtypes, but is challenged by subjective criteria, tissue sampling error, and lack of specific tumor markers. Anatomic imaging is essential for surgical planning of gliomas but is limited by its nonspecificity and its inability to depict beyond morphologic aberrations. The purpose of our study was to investigate dynamic susceptibility contrast-enhanced (DSC) MR imaging characteristics of the two most common subtypes of low-grade infiltrating glioma: astrocytoma and oligodendroglioma. We hypothesized that tumor blood-volume measurements, derived from DSC MR imaging, would help differentiate the two on the basis of differences in tumor vascularity. METHODS: We studied 25 consecutive patients with treatment-naïve, histopathologically confirmed World Health Organization grade II astrocytoma (n = 11) or oligodendroglioma (n = 14). All patients underwent anatomic and DSC MR imaging immediately before surgical resection. Histologic confirmation was obtained in all patients. Anatomic MR images were analyzed for morphologic features, and DSC MR data were processed to yield quantitative cerebral blood volume (CBV) measurements. RESULTS: The maximum relative CBV (rCBV(max)) in tumor ranged from 0.48 to 1.34 (0.92 ± 0.27, median ± SD) in astrocytomas and from 1.29 to 9.24 (3.68 ± 2.39) in oligodendrogliomas. The difference in median rCBV(max) between the two tumor types was significant (P < .0001). CONCLUSION: The tumor rCBV(max) measurements derived from DSC MR imaging were significantly higher in low-grade oligodendrogliomas than in astrocytomas. Our findings suggest that tumor rCBV(max) derived from DSC MR imaging can be used to distinguish between the two low-grade gliomas.
- Published
- 2005
8. Sarcoidosis of the pineal gland: an unusual presentation of neurosarcoidosis.
- Author
-
Isaac Yang, Amy Delpolyi, Michael Sughrue, James Rubenstein, Andrew Bollen, and Andrew Parsa
- Abstract
Abstract  Introduction Sarcoidosis is an inflammatory disease characterized by noncaseating granulomas that is rarely found as primary CNS pathology. We report an unusual case of sarcoidosis involving the pineal gland with radiographic, histopathology, and clinical data. Case report A 45-year-old man without evidence of systemic sarcoidosis presented with a history of gradual onset of blurry vision and diplopia that progressed over 3 months. MR imaging demonstrated an enhancing mass in the pineal region. A suboccipital craniotomy was performed with resection of the mass through a supra-cerebellar infratentorial approach. Histopathologic analysis did not reveal a pineoblastoma but instead revealed noncaseating granulomas within the pineal gland. Extensive hematologic laboratory examinations, cerebral spinal fluid studies, and cultures for infection were all negative. This mass lesion was diagnosed as solitary neurosarcoidosis of the pineal gland, without dissemination. The patient was treated with steroids and at 4-year follow-up is asymptomatic with an unremarkable MRI scan. Conclusion This is an unusual case of pineal sarcoidosis mimicking a tumor with associated MRI, CT and histopathologic findings reported together. Although rare, sarcoidosis of the pineal gland should not be excluded from a comprehensive differential diagnosis of an enhancing pineal region mass. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
9. Refractory Status Epilepticus in Suspect Encephalitis.
- Author
-
Carol Glaser, Sabrina Gilliam, Somayeh Honarmand, Jay Tureen, Daniel Lowenstein, Larry Anderson, Andrew Bollen, and Marylou Solbrig
- Subjects
ENCEPHALITIS ,PEOPLE with epilepsy ,ANTICONVULSANTS ,CLINICAL pathology ,NEUROLOGY ,PATHOLOGICAL physiology ,MEDICAL care ,PATIENTS - Abstract
Abstract Background The California Encephalitis Project (CEP) is a program designed to determine causes of encephalitis. We sought to determine whether there are any distinguishing characteristics of patients with encephalitis who develop refractory status epilepticus from those who do not. Methods Data from all patients in the CEP were retrospectively reviewed and analyzed. Diagnostic testing was performed for a panel of infectious agents and medical information collected using a standardized form. Encephalitis patients were subdivided into three categories: (i) patients with status epilepticus unresponsive to standard antiepileptic therapy who required general anesthetic coma for management (Group I), (ii) patients with seizures or status epilepticus responsive to standard antiepileptic therapy (Group II), and (iii) patients without seizures (Group III). Supplementary information was requested on Group I patients. Results Of 1,151 patients; 43 (4%) were classified as Group I, 459 (40%) as Group II, and 649 (56%) as Group III. Compared to Groups II and III, Group I patients were younger (median age = 10.0 years), more likely to have fever (93%), prodromal respiratory (57%) or gastrointestinal illness (64%), and less likely to have CSF pleocytosis (47%) or abnormal neuroimaging (16%). A causative infectious agent was verified in three of the Group I patients; and a putative agent in nine others. Supplementary information on Group I revealed that 28% died within 2 years and 56% were neurologically impaired or undergoing rehabilitation. Conclusions Encephalitis and refractory status epilepticus occur most commonly in the pediatric age group, an infectious etiology is usually not established, and outcomes are generally poor. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
10. CC chemokine receptor-2A is frequently overexpressed in glioblastoma.
- Author
-
Andrew Bollen and Nalin Gupta
- Abstract
Abstract  Macrophages and monocytes migrate in response to chemotactic cytokines such as monocyte chemoattractant protein 1 (MCP-1/CCL2) in a variety of tissues including the central nervous system. Overexpression of MCP-1 has been reported in glioblastoma (GBM), which correlates to prominent macrophage infiltration characterized by this tumor type, but whether MCP-1 receptor is also expressed by the neoplastic cells remains unclear. Expression of MCP-1 and its receptor, CC chemokine receptor 2 (CCR2), were examined in GBM using cDNA microarrays and validated in two independent microarray datasets. We investigated the expression of the CCR2A isoform in human glioma cell lines and GBM, and found overexpression of CCR2A in most GBM specimens examined when compared to normal brain tissues. CCR2A is mainly localized in the cytoplasm of neoplastic cells, and pronounced neuronal cytoplasmic CCR2A immunoreactivity in tumor-infiltrating area was associated with prior chemo/radiation therapy. Glioma cells ectopically overexpressing CCR2A demonstrated increased migration compared to vector-transfected cells in vitro. Inhibition of MCP-1 synthesis suppressed migration of CCR2A-overexpressed glioma cells. Our data suggest that CCR2A might be associated with the pathobiology of GBM such as host response to treatment and tumor cell migration. [ABSTRACT FROM AUTHOR]
- Published
- 2008
11. Type I collagen is overexpressed in medulloblastoma as a component of tumor microenvironment.
- Author
-
Andrew Bollen, Mark Israel, and Nalin Gupta
- Abstract
Abstract Medulloblastoma is the most common malignant brain tumor of children, and more specific and effective therapeutic management needs to be developed to improve upon existing survival rates and to avoid side-effects from current treatment. Gain of chromosome seven is the most frequent chromosome copy number aberration in medulloblastoma, suggesting that overexpression of genes on chromosome seven might be important for the pathogenesis of medulloblastoma. We used microarrays to identify chromosome seven genes overexpressed in medulloblastoma specimens, and validated using data from published gene expression datasets. The gene encoding the alpha 2 subunit of type I collagen, COL1A2, was overexpressed in all three datasets. Immunohistochemistry of tumor tissues revealed type I collagen in the leptomeninges, and in the extracellular matrix surrounding blood vessels and medulloblastoma cells. Expression of both type I collagen and the β1 subunit of integrin, a subunit of a known type I collagen receptor, localized to the same area of medulloblastoma. Adherence of D283 medulloblastoma cells to type I collagen matrix in vitro depends on the β1 subunit of integrin. Because medulloblastoma is characteristic of high vascularity, and because inhibition of type I collagen synthesis has been shown to suppress angiogenesis and tumor growth, our data suggest that type I collagen might be a potential therapeutic target for treating medulloblastoma. [ABSTRACT FROM AUTHOR]
- Published
- 2008
12. Controlled Cortical Impact in Swine:Pathophysiology and Biomechanics.
- Author
-
Geoffrey T. Manley, Guy Rosenthal, Maggie Lam, Diane Morabito, Donghong Yan, Nikita Derugin, Andrew Bollen, M. Margaret Knudson, and S. Scott Panter
- Published
- 2006
13. Limitations of diffusion-weighted imaging in distinguishing between a brain tumor and a central nervous system histoplasmoma.
- Author
-
Justin Smith, Alfredo Quiñones-Hinojosa, Joanna Phillips, Andrew Bollen, Michael McDermott, and Soonmee Cha
- Published
- 2006
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.